CareFirst BlueCross BlueShield — the largest health insurer in the mid-Atlantic region, serving Maryland, the District of Columbia, and portions of Virginia — manages pharmacy benefits through CVS Caremark across most plan types. In 2026, CareFirst's GLP-1 receptor agonist coverage follows a tiered structure: type 2 diabetes GLP-1s are covered with prior authorization on most formularies, weight-loss GLP-1s are available on select commercial plans with strict PA criteria, and CareFirst Community Health Plan Medicaid covers Wegovy for cardiovascular prevention and Zepbound for obstructive sleep apnea — but not for weight loss alone.
This guide maps which GLP-1 medications CareFirst covers under which diagnoses, details PA criteria and formulary variation across commercial, Medicare Advantage, and Medicaid lines of business, explains common denial reasons, and provides step-by-step coverage verification guidance. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | CareFirst Commercial | CareFirst Medicaid (MD) | CareFirst Medicare Advantage |
|---|---|---|---|
| Ozempic (semaglutide injection) | Covered — T2D with PA | Covered — T2D with PA | Covered — Part D formulary with PA |
| Mounjaro (tirzepatide injection) | Covered — T2D with PA | Covered — T2D with PA | Covered — Part D formulary with PA |
| Rybelsus (semaglutide tablets) | Covered — T2D with PA | Covered — T2D with PA | Covered — Part D formulary with PA |
| Trulicity (dulaglutide) | Covered — T2D with PA | Covered — T2D with PA | Covered — Part D formulary with PA |
| Wegovy (semaglutide 2.4 mg) | Covered for weight loss on select plans with PA; covered for MACE prevention | Covered for MACE prevention with PA (BMI ≥27 + ASCVD); not covered for weight loss alone | Covered per CMS Medicare GLP-1 Bridge demonstration (July 2026) |
| Zepbound (tirzepatide) | Covered for weight loss on select plans with PA | Covered for OSA with PA (BMI ≥30 + moderate-to-severe OSA); not covered for weight loss alone | Covered for OSA with PA |
| Saxenda (liraglutide 3 mg) | Covered on select plans with PA | Not covered | PA required |
Key policy dates:
April 15, 2025: Zepbound added to CareFirst Community Health Plan Maryland formulary for OSA indication
January 1, 2026: CareFirst Medicaid weight-loss exclusion confirmed — GLP-1s not covered when sole indication is weight management
July 1, 2026: CMS Medicare GLP-1 Bridge demonstration begins, expanding Wegovy and weight-loss GLP-1 access for CareFirst Medicare Advantage members
October 1, 2026: CVS Caremark reintroduces Zepbound to commercial formularies as a preferred option for plans that elect weight-loss GLP-1 coverage
Who this is for
CareFirst commercial members and their prescribers navigating GLP-1 prior authorization
CareFirst Community Health Plan Maryland Medicaid members and providers
CareFirst Medicare Advantage members exploring GLP-1 coverage options
Benefit verification specialists and hub teams handling CareFirst pharmacy claims
Market access teams at GLP-1 manufacturers tracking CareFirst policy changes
Employer benefits administrators evaluating CareFirst GLP-1 coverage by formulary
Source standard
Every fact in this guide is sourced from CareFirst formulary documents, CareFirst Community Health Plan Maryland publications, CVS Caremark formulary updates, CareFirst Medicare Advantage plan documents, and CMS publications dated 2025–2026. CareFirst coverage rules vary by formulary, plan type, state, and employer group. Always verify current coverage by calling the member services number on your CareFirst card or checking carefirst.com.
CareFirst program overview and GLP-1 relevance
CareFirst BlueCross BlueShield serves approximately 3.3 million members across Maryland, DC, and portions of Virginia. Key structural features relevant to GLP-1 coverage:
Pharmacy benefit manager: CVS Caremark manages pharmacy benefits for most CareFirst commercial, Medicaid, and Medicare Advantage plans. CareFirst uses multiple formulary structures depending on plan type
Formulary families: Commercial plans use Lowest Net Cost (LNC), Premium, and Select formularies; Medicare Advantage uses Essential and Complete formularies; Medicaid uses a closed formulary managed through CVS Caremark
Service area: Maryland, District of Columbia, and portions of northern Virginia
Plan types: Commercial (fully insured and self-funded), Individual/Family, Medicare Advantage (HMO, PPO, D-SNP), Medicaid managed care (Community Health Plan Maryland)
CareFirst Community Health Plan Maryland — GLP-1 coverage
CareFirst Community Health Plan Maryland (CareFirst CHPMD) is the Medicaid managed care plan. Its GLP-1 coverage rules are distinct from commercial plans and are governed by Maryland Medicaid policy.
Diabetes GLP-1 coverage
Ozempic, Mounjaro, Rybelsus, Trulicity, and other diabetic GLP-1 receptor agonists are covered for the treatment of type 2 diabetes with prior authorization. Prescribers must submit documentation confirming T2D diagnosis.
Wegovy for cardiovascular prevention
Wegovy is covered when prescribed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) who are overweight or obese. PA criteria include:
Patient is 18 years or older
Established and documented ASCVD (prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease)
Overweight or obese (BMI ≥27 kg/m² documented within last 90 days)
Patient does not have type 1 or type 2 diabetes
Prescriber attestation that medication is prescribed in accordance with prescribing information, including screening for contraindications
Co-administration with other semaglutide products or other GLP-1 receptor agonists is excluded
Wegovy is not covered when the sole indication is chronic weight management for patients who are obese (BMI ≥30) or overweight (BMI ≥27) with comorbidities — even though Wegovy is FDA-approved for that purpose. The Medicaid program only covers the cardiovascular prevention pathway.
Zepbound for obstructive sleep apnea
Zepbound was added to the CareFirst CHPMD formulary on April 15, 2025, for the treatment of obstructive sleep apnea. PA criteria include:
Patient is 18 years or older
Diagnosis of moderate-to-severe obstructive sleep apnea
BMI ≥30 kg/m²
Patient does not have type 1 or type 2 diabetes
Zepbound is not covered for weight loss alone under CareFirst Medicaid.
Weight-loss exclusion
CareFirst CHPMD explicitly states: "These medications are not covered when used for weight loss alone. Weight loss is not a covered benefit." This reflects Maryland Medicaid's overall policy restricting GLP-1 coverage to FDA-approved indications other than obesity treatment.
PA process for CareFirst Medicaid
PA requests are submitted to CVS Caremark at 1-877-418-4133
CVS issues a preauthorization decision within 24 hours of the request
If additional information is needed, providers have up to 14 calendar days to submit
Adverse determinations are communicated within 24 hours
Specialty drugs are dispensed through CVS Pharmacy Specialty Services (1-800-237-2767) and select University of Maryland Medical System pharmacies
CareFirst commercial — GLP-1 coverage
Formulary structure
CareFirst commercial plans use multiple formularies, each with different GLP-1 tier placement and coverage rules:
Lowest Net Cost (LNC) Formulary: Most cost-restrictive; GLP-1 weight-loss coverage depends on employer election
Premium Formulary: Broader coverage; GLP-1s for weight loss more likely to be included
Select Formulary: Intermediate; coverage varies by employer group election
PA criteria for commercial weight-loss GLP-1s
For commercial plans that cover weight-loss GLP-1s, PA typically requires:
BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, elevated waist circumference)
Documentation of lifestyle modification attempts
Step therapy may apply — some plans require trial of Contrave, Qsymia, or Saxenda before Wegovy or Zepbound
PA duration limited — initial approval typically 3–6 months, with renewal requiring documented weight loss (at least 5% of baseline body weight) and continued adherence
Self-funded vs. fully insured plans
For self-funded employer plans, the employer decides whether to include GLP-1 weight-loss coverage. This means:
Two CareFirst members with identical medical profiles may have different GLP-1 coverage depending on whether their employer elected the GLP-1 benefit
Self-funded plans may use different formularies and PA criteria than fully insured plans
Always verify the specific formulary and coverage rules for the member's plan, not just the CareFirst brand
CareFirst Medicare Advantage — GLP-1 coverage
CareFirst offers multiple Medicare Advantage plans with Part D prescription drug coverage:
CareFirst BlueCross BlueShield Group Advantage (PPO): Uses a 5-tier formulary (Generic, Generic, Preferred Brand, Non-Preferred Drug, Specialty)
CareFirst BlueCross BlueShield Advantage DualPrime (HMO-SNP): D-SNP plan with its own formulary
Essential and Complete plans: Different formulary structures
GLP-1 coverage in Medicare Advantage
T2D GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity): Covered on Part D formularies with PA
Wegovy for MACE prevention: Covered per FDA-approved indication
Weight-loss GLP-1s: Historically excluded under Medicare Part D's exclusion of weight-loss drugs. CMS policy is changing:
July–December 2026: CMS Medicare GLP-1 Bridge demonstration provides temporary coverage pathway for Medicare beneficiaries
January 2027: BALANCE model launches for broader Medicare GLP-1 obesity coverage
Medicare-specific PA rules
Previous PAs cannot transfer between plan years due to CMS regulation
Early coverage determination requests can start December 1 before the new benefit year
Transition supply: Members get a one-time, one-month supply of current medications within the first 90 days of enrollment
Prior authorization workflow
Step 1: Verify formulary and plan type
Before initiating PA, determine:
Which CareFirst formulary applies (LNC, Premium, Select, Essential, Complete, Medicaid)
Whether the plan covers weight-loss GLP-1 medications at all
Whether the member's indication (T2D, weight loss, MACE prevention, OSA) is a covered benefit
Step 2: Confirm clinical criteria
For the relevant indication, confirm that documentation supports:
T2D: Documented diagnosis with ICD-10 code, oral hypoglycemic trial history
Weight loss: BMI threshold met, lifestyle modification documented, step therapy completed if required
MACE prevention: ASCVD documentation (MI, stroke, PAD), BMI ≥27, no diabetes diagnosis
OSA: Moderate-to-severe OSA diagnosis, BMI ≥30, no diabetes diagnosis
Step 3: Submit PA to CVS Caremark
Prescribers submit PA through:
CVS Caremark provider portal
Phone: 1-877-418-4133
Fax: Use the standard PA fax form
Step 4: Decision timeline
CVS Caremark issues PA decisions within 24 hours of receiving the request
If additional information is needed, providers have up to 14 calendar days to submit
Expedited reviews available for urgent clinical situations
Step 5: Appeal if denied
If PA is denied:
Request the specific denial reason and reference number
Gather supporting clinical documentation
Submit a first-level appeal to CareFirst/CVS Caremark
If denied, request a second-level appeal or external review
For Medicare Advantage members, follow CMS coverage determination and redetermination process
Coverage verification checklist
When calling CareFirst member services or CVS Caremark to verify GLP-1 coverage, ask:
Which formulary applies to this member's plan?
Is GLP-1 coverage available for the member's diagnosis (T2D / weight loss / MACE / OSA)?
What PA criteria apply?
Is step therapy required? If so, which medications must be tried first?
What is the tier placement and expected copay/coinsurance?
Which specialty pharmacy is in-network for GLP-1 medications?
What is the PA approval duration and renewal criteria?
Common denial reasons and how to address them
| Denial Reason | Explanation | What to Do |
|---|---|---|
| Weight-loss exclusion | Plan excludes GLP-1 for weight loss | Verify if formulary covers weight-loss GLP-1; explore MACE or OSA pathways if applicable |
| BMI below threshold | Documented BMI below 30 (or 27 with comorbidity) | Submit most recent BMI documentation; confirm criteria for the specific plan |
| Missing T2D diagnosis | PA for diabetic GLP-1 lacks documented T2D | Ensure ICD-10 code E11.x is included with supporting clinical notes |
| Step therapy not met | Required prior trial of alternative medication | Document trial and failure of required alternatives; submit pharmacy fill records |
| Insufficient documentation | PA submission missing required clinical evidence | Gather complete records: BMI, labs, medication history, lifestyle modification documentation |
| Non-formulary drug | Requested GLP-1 not on member's formulary | Request formulary exception with medical necessity justification |
What to monitor
CVS Caremark formulary updates: CVS Caremark's May 2026 announcement reintroducing Zepbound to commercial formularies (effective October 2026) will affect CareFirst plans that use CVS Caremark template formularies
Foundayo (orforglipron) access: CVS Caremark removed the new-to-market block on Foundayo effective June 1, 2026, for plans that approve coverage — this oral GLP-1 may become a preferred option on CareFirst formularies
Maryland Medicaid policy: Maryland is among states where GLP-1 Medicaid coverage remains limited to non-obesity indications; legislative action could expand coverage
CMS BALANCE model: The 2027 BALANCE model could significantly expand GLP-1 obesity coverage for CareFirst Medicare Advantage members
Employer plan redesign: Self-funded employer groups may add or remove GLP-1 weight-loss coverage during annual renewal
Sources
CareFirst Community Health Plan Maryland. "Health & Wellness Fall 2025 Newsletter." https://www.carefirst.com/medicaid/attachments/CFCHP-MD-Fall-Newsletter-10-25.pdf
CareFirst Community Health Plan Maryland. "2026 Comprehensive Formulary." https://www.carefirst.com/medicaid/attachments/CHPMD-JAN-0126-Comprehensive-Formulary.pdf
Maryland Department of Health. "Wegovy Preauthorization Criteria — Coverage of Wegovy for Overweight or Obese Adults with Cardiovascular Disease." Transmittal PT35-25. https://www.carefirst.com/medicaid/attachments/PT35-25-Coverage-of-Wegovy-for-Overweight-or-Obese-Adults-with-Cardiovascular-Disease.pdf
CareFirst BlueCross BlueShield. "Medicare Advantage Prescription Drug Plan Management." https://www.carefirst.com/medicare-options/compare-medicare-plans/drug-management-programs.html
CareFirst BlueCross BlueShield. "Prescription Drug Benefits — Congress Plans." https://www.carefirst.com/congress/find-the-right-plan/drug-coverage/understanding-drug-coverage.html
CareFirst BlueCross BlueShield. "Federal Employee Prescription Drug Benefits." https://www.carefirst.com/fedhmo/plan-information/prescription-drug-benefits.html
CVS Health. "CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options." May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
CMS.gov. "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." 2026. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
Word & Brown General Agency. "Weight Loss Drugs (GLP-1) Insurance Coverage Breakdown By Carrier." Updated May 1, 2026. https://www.wordandbrown.com/NewsPost/Weight-Loss-Drugs-(GLP-1)-Coverage
